AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

Frequent colorectal polyp diagnoses in first- and second-degree relatives are associated with an increased risk for colorectal cancer (CRC), especially early-onset CRC. Researchers evaluated the ...

How much is Canopy Growth Corp stock worth? Invest with precise valuations. Get Report.